Acute Promyelocytic Leukemia: Pathophysiology, Diagnosis and Clinical Management
Hematology Reports · 28.11.2025 · 17 (6) · 66
DOI: 10.3390/hematolrep17060066 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematology Reports, online erschienen am 28.11.2025. Verfasst von Meryeme Abddaoui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medical Sciences and Translational Research, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, Sidi Mohammed Ben Abdellah Unive…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Institute de Recherche sur le Cancer (IRC, www.irc.ma) under the Scientific Publi-cation Grant Program, the Institute de Recherche sur le Cancer.
Abstract (Originalsprache)
Background/Objectives: Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by the t(15;17)(q24;q21) translocation, generating the PML::RARA fusion gene that blocks myeloid differentiation and drives leukemogenesis. Despite advances in therapy, early mortality remains a major challenge due to severe coagulopathy. This review aims to summarize recent insights into APL pathophysiology, diagnostic approaches, and management strategies.
Methods
We performed a comprehensive review of the literature addressing the molecular mechanisms of APL, its associated coagulopathy, and current diagnostic and therapeutic standards, with a focus on evidence-based recommendations for clinical practice.
Results
The hallmark PML: RARA oncoprotein disrupts nuclear body function and retinoic acid signaling, resulting in differentiation arrest and apoptosis resistance. APL-associated coagulopathy arises from overexpression of tissue factor, release of cancer procoagulant, inflammatory cytokines, and annexin II-mediated hyperfibrinolysis. Diagnosis requires integration of cytomorphology, immunophenotyping, coagulation studies, and molecular confirmation. Immediate initiation of all-trans-retinoic acid (ATRA) upon clinical suspicion, combined with aggressive supportive care, is critical to control bleeding risk.
Conclusions
APL is now a highly curable leukemia when recognized early and treated with targeted therapy. Rapid diagnosis, prompt ATRA administration, and meticulous hemostatic support are essential to reduce early mortality. Further refinements in minimal residual disease monitoring are expected to improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Medical Sciences and Translational Research, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, Sidi Mohammed Ben Abdellah University, Fès 30070, Morocco.
- Institute of Cancer Research, Fès 30000, Morocco.
- Department of Hematology, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, Fès 30070, Morocco.
ORCID-Profile: Meryeme Abddaoui, Youssef Aghlallou
Förderung
- the Institute de Recherche sur le Cancer (IRC, www.irc.ma) under the Scientific Publi-cation Grant Program
- the Institute de Recherche sur le Cancer
Zitieren
APA
Abddaoui, M., Aghlallou, Y., Tlemçani, I., & Amrani Hassani, M. (2025). Acute Promyelocytic Leukemia: Pathophysiology, Diagnosis and Clinical Management. Hematology Reports, 17(6), 66. https://doi.org/10.3390/hematolrep17060066
Vancouver
Abddaoui M, Aghlallou Y, Tlemçani I, Amrani Hassani M. Acute Promyelocytic Leukemia: Pathophysiology, Diagnosis and Clinical Management. Hematology Reports. 2025;17(6):66. doi:10.3390/hematolrep17060066
BibTeX
@article{Abddaoui2025,
author = {Abddaoui, Meryeme and Aghlallou, Youssef and Tlemçani, Imane and Amrani Hassani, Moncef},
title = {Acute Promyelocytic Leukemia: Pathophysiology, Diagnosis and Clinical Management},
journal = {Hematology Reports},
year = {2025},
volume = {17},
number = {6},
pages = {66},
doi = {10.3390/hematolrep17060066}
}
EUVIMED